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INTRODUCTION
The assessment of ﬁbromyalgia (FM) is challenging be-
cause there are no biomarkers for this condition. Clini-
cians must rely upon patient-reported symptoms in order
to understand the complexities of this condition. While in
1990, the American College of Rheumatology (ACR) devel-
oped research classiﬁcation criteria involving tender point
counts, it has only been within the past year that the ACR
proposed clinical diagnostic criteria (1). Historically,
many symptoms have been thought to be associated with
FM. In order to narrow the ﬁeld to those symptoms with
the greatest clinical relevance, a working group within
Outcome Measures in Rheumatology (OMERACT) con-
ducted several Delphi exercises within both patients and
clinicians to obtain consensus regarding which domains
should be assessed in clinical trials for FM (2,3). The
instruments to be reviewed herein reﬂect the clinically
relevant domains deﬁned by this OMERACT working
group.
A wide variety of instruments have been used to index
the OMERACT domains for FM. Many of the instruments
were developed for use generically or have been borrowed
from other clinical populations. In recent phase II and III
clinical trials of medications for FM, wide variation was
observed in the selection of domain indices (Table 1).
While many of these measures are reviewed elsewhere in
this special issue, we have selected a representative mea-
sure from each of the following domains of relevance: pain
(Brief Pain Inventory), fatigue (Multidimensional Fatigue
Inventory), sleep disturbance (Medical Outcomes Study
Sleep Scale), and cognitive dysfunction (Multiple Ability
Self-Report Questionnaire). Mood and functional status
are also important domains for FM; however, the instru-
ments most commonly used to assess these domains are
reviewed elsewhere in this special issue and will not be
repeated here (e.g., mood [Hospital Anxiety and Depres-
sion Scale] and functional status [Short Form 36]). Recent
work in the development of responder indices suggests
that either these speciﬁc instruments or other measure-
ment tools from within the same domain can be used to
differentiate responders from nonresponders in clinical
treatment trials for FM (4). The precision by which these
domains will be able to be assessed in the future is likely
to be enhanced as newer measurements are being devel-
oped using either classic test construction methods or
methods such as item response theory and computer adap-
tive testing, as is being done in the National Institutes of
Health Patient-Reported Outcomes Measurement System
(5).
FIBROMYALGIA IMPACT QUESTIONNAIRE
(FIQ)
Description
Purpose. The FIQ was developed in the late 1980s by
clinicians at Oregon Health & Science University (OHSU)
to assess the total spectrum of problems related to ﬁbro-
myalgia (FM) and associated responses to therapy (6). The
FIQ was ﬁrst published in 1991 (7) and modiﬁed in both
1997 and 2002 to reﬁne items and to clarify the scoring
system (6). The FIQ was revised in 2009 (FIQR) to better
reﬂect current understanding of FM and to address limi-
tations of the original FIQ while retaining its essential
properties (8).
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Content. The original FIQ (1991) covered 3 domains:
function, overall impact, and symptoms. The function do-
main contained 10 physical functioning items related to
the ability to perform large muscle tasks, including the
ability to do shopping, do laundry, prepare meals, wash
dishes by hand, vacuum a rug, make beds, walk several
blocks, visit friends or relatives, do yard work, and drive a
car. The overall impact domain contained 2 items asking
about the number of days individuals felt well and the
number of days they were unable to work because of FM
symptoms. The symptoms domain contained 7 items using
10-cm visual analog scales on which patients rate work
difﬁculties, pain, fatigue, morning tiredness, stiffness,
anxiety, and depression. The 1997 version modiﬁed items
about “work” to include “housework,” and a new item
about “climbing stairs” was added to the functioning do-
main. Finally, the 1997 version added hash marks (i.e.,
vertical lines) every 1 cm to the formatting of all visual
analog scales. The 2009 FIQR has the same 3 domains as
the original FIQ (function, overall impact, and symptoms),
but differs in several ways. First, the physical functioning
domain was reduced to 9 items and modiﬁed to reﬂect a
better balance between large-muscle activities in the upper
and lower extremities, and that would have less sex and
ethnicity bias. The physical functioning items in-
clude the ability to brush or comb hair; walk continuously
for 20 minutes; prepare a homemade meal; vacuum,
scrub, or sweep ﬂoors; lift and carry a bag full of gro-
ceries; climb 1 ﬂight of stairs; sit in a chair for 45 minutes;
and go shopping for groceries. The overall impact domain
was completely revised to reﬂect the overall impact of
FM on functional ability and the overall impact of FM on
the perception of reduced function. The symptom do-
main retained items on pain, fatigue, morning tiredness,
stiffness, anxiety, and depression and added 4 additional
items on tenderness, memory, balance, and environmental
sensitivity.
Number of items. The original FIQ (1991) had 19 items
capturing 3 domains. The 1997 version of the FIQ retained
the same domains but added an additional item for a total
of 20 items. In the 2009 FIQR, the ﬁrst domain (physical
function) has 9 items, the second domain (overall impact)
has 2 items, and the third domain (symptoms) has 10 items
for a total of 21 items.
Response options/scale. The physical functioning items
in the 1991 and 1997 versions of the FIQ are rated on a 0–3
scale that best reﬂects the patient’s ability to do the activity
(0  always, 1  most, 2  occasionally, 3  never). The
overall impact items are rated on a 0–7 scale for the num-
ber of days the patient felt well and the number of days the
patient missed work, respectively. The symptom items are
visual analog scales (0–10 cm), with higher numbers indi-
cating greater symptomatology. All of the items in the 2009
FIQR are 0–10 numeric rating scales using 11 boxes, with
higher numbers reﬂecting greater severity.
Recall period for items. The recall period is over the
past week.
Endorsements/examples of use. Since 1991, the FIQ has
been one of the most frequently used assessment tools in
the evaluation of FM, and has been particularly useful as
an outcome measure in FM clinical trials. The FIQ has
been cited in over 300 articles between 1991 and 2010 (see
URL: www.myalgia.com/FIQ/FIQ_REFS_2010.htm for a
complete listing of article abstracts). The use of the FIQR
in clinical studies has not yet been published.
Practical Application
How to obtain. The FIQ and the FIQR are free for aca-
demic and clinical use. An online license to use the FIQ is
available by registering at URL: www.myalgia.com/FIQ/
FIQ_academic_agreement.htm. The original FIQ is pub-
lished in reference (7). The 1997 version with the 2002
scoring revision was published in 2005 (6) and is also
available at URL: www.myalgia.com/FIQ/FIQ_B.htm. The
FIQR is available at this same web site and was published
in 2009 (8).
Method of administration. The FIQ and FIQR are ad-
ministered as self-report questionnaires.
Table 1. Outcome measures in ﬁbromyalgia trials of
Food and Drug Administration–approved medications
Fibromyalgia
domain Outcome measure
Pain Visual analog scale (daily diary)
Numeric rating scale (0–10) (daily
diary)
Fibromyalgia Impact Questionnaire
pain (0–10)
Brief Pain Inventory pain severity
scores (0–10)
Short Form 36 bodily pain
Tenderness Dolorimetry (tender point threshold)
Fatigue Visual analog scale (0–100) (daily
diary)
Fibromyalgia Impact Questionnaire
fatigue (0–10)
Short Form 36 vitality
Multidimensional Fatigue Inventory
Multidimensional Assessment of
Fatigue
Sleep Numeric rating scale (0–10) daily
diary of sleep quality
Fibromyalgia Impact Questionnaire
morning rested feelings (0–10)
Medical Outcomes Study sleep scale
Depression Beck Depression Inventory
Hamilton Depression Rating Scale
Fibromyalgia Impact Questionnaire
depression (0–10)
Hospital Anxiety and Depression
Scale depression
Anxiety Fibromyalgia Impact Questionnaire
anxiety
Hospital Anxiety and Depression
Scale anxiety
Cognition Multiple Abilities Self-Report
Questionnaire
Stiffness Fibromyalgia Impact Questionnaire
stiffness (0–10)
Physical function Short Form 36 physical function
Fibromyalgia Impact Questionnaire
physical function
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Scoring. The 1991 and 1997 FIQ versions have similar
scoring. The ﬁnal scores for each item of the FIQ should
range from 0 (no impairment) to 10 (maximum impair-
ment). The physical functioning items are rated on a
4-point Likert-type scale. Raw scores on each question can
range from 0 (always) to 3 (never). Because some patients
may not do some of the tasks listed, they are given the
option of deleting questions from scoring. The scores for
the items that the patient has rated are summed and di-
vided by the number of questions answered. An average
raw score between 0 and 3 is obtained. This value is then
multiplied by 3.33. The ﬁrst impact item that asks the
number of days in the past week the patient felt well is
reverse scored so that a higher number indicates impair-
ment. Raw scores range from 0–7 and are then multiplied
by 1.43. The second impact item is scored as the number of
days the patient was unable to do regular work activities.
Raw scores range from 0–7 and are then multiplied by
1.43. Symptom items are visual analog scales. In the 1991
version, the items are scored in number of cm from 0–10.
Because the 1997 version added hash marks to all of the
visual analog scales, these items are scored in numerical
increments from 0–10, allowing scores to include 0.5 if the
patient marks the space between 2 vertical lines. In the
1991 version, patients were instructed to cross out items 3
and 4 if they did not work. Therefore, the total maximum
FIQ score was reduced from 100 to 80. With the 1997
revision in which questions 3 and 4 were modiﬁed to
include housework, the total FIQ scores should always
range from 0–100. In 2002, a modiﬁcation of the scoring
was recommended to address incomplete data. In order to
maintain homogeneity on a 0–100 continuum, the ﬁnal
score is to be adjusted to reﬂect a ﬁnal maximum score of
100. For example, if a patient missed 2 questions, the total
recorded score should be adjusted by a factor of 10/8. The
FIQR has 21 individual items and all items are based on an
11-point numeric rating scale of 0–10, with 10 being the
“worst.” The summed score for the function domain,
which contains 9 items (range 0–90) is divided by 3; the
summed score for overall impact, which contains 2 items
(range 0–20) is not changed; and the summed score for
symptoms, which contains 10 items (range 0–100) is di-
vided by 2. As in the FIQ, the total maximum score for the
FIQR is 100. The weighting of the 3 domains is different
from the FIQ in that function accounts for 30% of the total
score as opposed to 10% in the FIQ, the symptom domain
makes up 50% of the score instead of 70% in the FIQ, and
the overall impact domain remains the same as the FIQ at
20% (8).
Score interpretation. The ﬁnal scores for each of the
FIQ and FIQR items range from 0 (no impairment) to 10
(maximum impairment). The total maximum score for
both the FIQ and the FIQR is 100, which represents the
maximum impact of FM on the patient.
Respondent burden. It takes approximately 3–5 min-
utes to complete the FIQ. The FIQR is estimated to take
just over 1 minute to complete.
Administrative burden. The FIQ and FIQR are easily
administered by handing the questionnaires to the partic-
ipant. The scales include simple instructions for the re-
spondents. No formal training is required for the FIQ or
FIQR. Scoring is relatively simple for both the FIQ and
the FIQR but the use of numeric rating scoring for all of the
FIQR items further simpliﬁes the scoring and allows for
use of electronic versions of the FIQR that can be admin-
istered online as was done in the validation study (8).
Translations/adaptations. The FIQ has been translated
from English into 12 languages: Czech (Czech Republic),
Dutch (The Netherlands), French (France and Canada),
German (Germany), Hebrew (Israel), Italian (Italy), Korean
(Korea), Polish (Poland), Romanian (Romania), Spanish
(Argentina and Spain), Swedish (Sweden), Turkish (Tur-
key; see URL: www.myalgia.com/FIQ/FIQ_B.htm for more
information on translations).
Psychometric Information
Method of development. The initial version of the FIQ
was based on an intake questionnaire used by the OHSU
rheumatology clinic and informal discussions with pa-
tients with FM. This FIQ was mailed at weekly intervals
for a total of 6 weeks to 64 women with FM, along with the
Arthritis Impact Measurement Scale (AIMS). A second
group of 25 women with FM attending the OHSU Fibro-
myalgia Treatment Clinic completed the FIQ as part of
their routine clinical evaluation. The construct validity,
test–retest reliability, and content relevance of the FIQ
were assessed in these 2 groups of patients (6,7). The FIQR
was based on previous experience with the FIQ and pa-
tients’ evaluation of important symptoms (8). The new
questionnaire was tested in a focus group of 10 female
patients with FM. Following discussions among the pa-
tients and investigators, agreement was reached on the
ﬁnal version of the FIQR. The FIQR was then tested in an
online survey that was completed by patients with FM,
rheumatoid arthritis (RA), systemic lupus erythemato-
sus (SLE), or major depressive disorder (MDD), and
healthy controls. The participants also completed the
original FIQ and the 36-item Short Form Health Survey
(SF-36).
Acceptability. The FIQ was originally developed to as-
sess the current health status of women with FM, and may
therefore have a sex bias, particularly in the functional
items in which several of these questions relate to activi-
ties that are more likely to be performed by women. The
functional questions were intended for a relatively afﬂuent
patient who was assumed to have possession of a car, a
vacuum cleaner, and a washing machine and may there-
fore not generalize to all patients with FM. The FIQ also
has problems related to the deletion of physical function
items deemed “not applicable” by the respondent, which
may result in an underestimation of functional severity.
Some patients report difﬁculty understanding the scoring
of the physical function questions and note that the ques-
tions do not allow them to rate the degree of difﬁculty in
performing the activity. For example, a patient may report
that they were “always” able to do shopping even though
it took a great deal of time and effort to complete the task.
The FIQ functional items are oriented toward high levels
of disability, resulting in a potential ﬂoor effect. For exam-
ple, in one study, 12% of patients scored a 0 on the FIQ
physical function score (i.e., no dysfunction) (9). The FIQR
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was developed to correct some of the problems with the
FIQ. In particular, the physical functioning items were
revised to have less sex and ethnicity bias than the FIQ and
to improve the ease of scoring the functional activities on
a 0–10 scale ranging from “no difﬁculty” to “very difﬁcult”
(8).
Reliability. In the original 1991 study to evaluate the
FIQ, the test–retest reliability (Pearson’s r) was assessed by
the weekly recording of data over 6 weeks. The reliability
ranged from 0.56 on the pain score to 0.95 for physical
function (7). The internal consistency (Cronbach’s alpha)
was not reported in the original analysis. The Cronbach’s
alpha for the FIQR was 0.95, with item-total correlations
ranging from 0.56–0.93. Test–retest reliability was not
determined for the FIQR (8).
Validity. The content validity of the original FIQ was
assessed from an analysis of missing data for each item.
Missing data from the physical functioning items were
limited to 11% of patients who did not do dishes by hand
and 20% who did no yard work. Because many patients
were not working outside the home, the 2 work items of
the original FIQ were not relevant for 38% of the patients
(6,7). In the validation study of the FIQR, patient sugges-
tions about content and wording of the instrument during
the focus group meeting contributed to the face validity of
the ﬁnal version of the FIQR. Content validity of the FIQR
was suggested by strong correlation between the FIQR and
the SF-36. For example, the FIQR function domain was
most highly correlated with the SF-36 physical function-
ing subscale (8). The construct validity of the 1991 FIQ
was determined by measuring the correlation of the FIQ
individual items with the AIMS. The FIQ physical func-
tioning items had a signiﬁcant correlation (r  0.67) with
the AIMS lower-extremity physical function component
score. The pain, depression, and anxiety items of the FIQ
showed signiﬁcant correlations with the corresponding
AIMS scales (0.69, 0.73, and 0.76, respectively). The AIMS
visual analog of syndrome impact correlated least robustly
with the FIQ items, the highest correlation being with pain
(r  0.48). Item correlations with the AIMS syndrome
activity question tended to be higher, ranging from 0.28–
0.83. A principal components analysis yielded 5 factors.
The 10 physical functioning questions loaded on the ﬁrst
factor with component loading ranging from 0.50 to 0.95.
Factor 2 consisted of work difﬁculty, feeling good, pain,
fatigue, rest, and stiffness. Anxiety, depression, and days
of work missed all loaded on separate factors (6,7). Con-
vergent validity was assessed by comparing the FIQR to
both the SF-36 and the FIQ. The 3 domains of the FIQR
and the associated individual items correlated closely
with the corresponding subscales on the SF-36. Each of the
3 FIQR domains was also highly correlated with the total
FIQR score. There was a strong correlation (0.88) between
the FIQR and the FIQ, suggesting that the questionnaires
are capturing similar information about the impact of FM.
The mean total score of the FIQR was4 points lower than
the mean FIQ total score, which was attributed to the
change of the weighting in the FIQR scoring (8). Each of
the 3 FIQR domains predicted unique variance in SF-36
domains, providing evidence for discriminant validity.
Discriminant validity was also evaluated by comparing the
FIQR total scores in patients with FM with the scores in
healthy controls, patients with RA or SLE, and patients
with MDD. The FM FIQR scores were signiﬁcantly higher
than in the other 3 groups (8).
Ability to detect change. The FIQ has been most com-
monly used as an outcome measure in treatment trials and,
in general, has demonstrated an ability to detect clinical
change (6). The FIQ total score was also included as an
outcome measure in trials of the 3 US Food and Drug
Administration–approved medications for FM, pregabalin,
duloxetine, and milnacipran (10–12). For example, in a
pooled analysis of 4 placebo-controlled, double-blind
studies of duloxetine in FM, the total FIQ scores improved
signiﬁcantly in the duloxetine groups compared with pla-
cebo, with a mean (SE) reduction of 12.62 (0.61) in the
duloxetine patients compared with a mean (SE) reduction
of 8.2 (0.69) in the placebo group (P 0.001) (13). A recent
study suggested that a 14% change or an absolute change
of 8.1 (95% conﬁdence interval 7.6–8.5) in the FIQ total
score represented a clinically meaningful change in FM
status (i.e., minimum clinically important difference). The
minimum clinically important difference was determined
by calculating the percentage change in the FIQ total score
from baseline and linking this to each patient’s global
assessment of change score (14).
References. The validation of the original FIQ is pub-
lished in an article by Burckhardt et al (7). A review of
the development, operating characteristics, and uses of
the FIQ was done by Bennett (6) and the validation study
of the FIQR is found in the Bennett et al publication in
2009 (8).
Critical Appraisal of Overall Value to the
Rheumatology Community
Strengths. FM is associated with multiple symptoms
and functional impairment. The FIQ and FIQR are useful
assessment tools in FM because they evaluate the total
spectrum of problems related to FM, including functional
impairment, overall impact, and FM-related symptoms.
The FIQ total score has proved to be a useful outcome
measure in key clinical trials of FM.
Caveats and cautions. The FIQ functional items are ori-
ented toward high levels of disability, resulting in a pos-
sible ﬂoor effect. Because the FIQ was originally devel-
oped in a patient population of relatively afﬂuent women,
there is a potential problem with sex and ethnicity bias.
Although the individual domains and/or items on the FIQ
were not originally intended to be used in isolation, some
recent studies have reported single-item or domain scores
from this instrument. The internal consistency (Cron-
bach’s alpha) was not reported in the original analysis of
the FIQ. The FIQR was designed to correct some of the
problems with the FIQ, but has not yet been tested in the
context of clinical trials. Test–retest reliability was not
determined for the FIQR.
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Clinical usability. The FIQ and FIQR are brief, self-
report questionnaires that assess the impact of FM on
patients. The FIQ has most commonly been used in clini-
cal studies, but has the potential for use in the clinical
setting to monitor patients’ response to treatment over time.
Research usability. The FIQ has been used in large-
scale clinical trials of therapeutics for FM, supporting its
ability to assess and detect change in FM.
BRIEF PAIN INVENTORY (BPI)
Description
Purpose. The BPI was designed to measure multiple
clinically relevant aspects of pain such as pain intensity
and interference from pain in cancer populations (15).
The BPI was originally called the Wisconsin Brief Pain
Questionnaire (16). Subsequently, support for its valid
use in noncancer populations such as musculoskeletal,
neuropathic, and other central pain conditions has been
established (17,18). There are 2 versions; the short ver-
sion is the most commonly used and is often included in
the context of clinical trials. This is the version that pos-
sesses most foreign language translations. A longer, less
frequently used version is available that includes more
pain descriptors and may have clinical utility; however,
the developers recommend the short form for most appli-
cations. Only the shorter form will be considered here.
Content. The BPI assesses for the presence of pain, pain
intensity (i.e., worse, least, average, current), and func-
tional interference from pain (i.e., activity, mood, walking
ability, normal work, relations with others, sleep, life en-
joyment). It also catalogs the types of pain medications
being used, the percentage of pain relief obtained from
medications, and assesses the distribution of pain via a
body map.
Number of items. The BPI contains a total of 15 items.
Response options/scale. The BPI uses a mixture of
item types. Item 1 querying about the presence of pain is a
dichotomous “yes,” “no.” Item 2, the body map, asks that
areas of pain be shaded and an “X” placed on the body
region that hurts the most. Items 3–6 (intensity items)
utilize a 0 (no pain) to 10 (pain as bad as you can imagine)
11-point rating scale. Item 7 is an open-ended response to
list pain medications. Item 8 (percentage of pain relief)
ranges from 0% (no relief) to 100% (complete relief). Item
9 (a–g) inquires about interference using an 11-point nu-
meric rating scale. Each item ranges between 0 (does not
interfere) and 10 (completely interferes).
Recall period for items. The time frame for the BPI is
typically based upon “the past week” but some versions
allow for the past 24 hours.
Endorsements/examples of use. The BPI is widely used
in clinical trials for pain and in pain research generally. It
is one of the instruments recommended by the Initiative
on Methods, Measurement, and Pain Assessment in Clin-
ical Trials group (19) for inclusion in any clinical trial
evaluating pain.
Practical Application
How to obtain. The BPI is available through the follow-
ing address: The Department of Symptom Research, Attn:
Assessment Tools, The University of Texas MD Anderson
Cancer Center, 1515 Holcombe Boulevard, Unit 1450,
Houston, TX 77030. Phone: 713-745-3805. The BPI is
available free of charge for nonfunded academic research.
For funded academic research there is a charge per project
(e.g., $300) and a charge for commercial research (e.g.,
$800 per project).
Method of administration. The BPI can be administered
as a self-report questionnaire or as an interview.
Scoring. While some of the items represent single-item
values, pain intensity, indexed by the Pain Severity Score,
is calculated by obtaining the mean of the 4 pain intensity
items. The Pain Interference Score is obtained by calculat-
ing the mean of the 7 interference items.
Score interpretation. The Pain Severity Score has a
maximum value of 10 (i.e., “pain as bad as you can imag-
ine”) and a minimum value of 0 (i.e., “no pain”). The Pain
Interference Scale similarly has a maximum value of 10
(i.e., “completely interferes”) to 0 (i.e., “does not inter-
fere”). The BPI is easily scored by hand.
Respondent burden. It takes approximately 5 minutes
to complete the BPI.
Administrative burden. The BPI is easily administered
by handing the questionnaire to the participant or by ask-
ing each question verbally. Scoring is accomplished by
calculating 2 means, which can be done in 5 minutes.
Translations/adaptations. Validated translations are
available for the following languages: English, Spanish,
Italian, Russian, Norwegian, Greek, German, Japanese,
Chinese, Arabic, Bulgarian, Cebuano, Croatian, Czech, Fil-
ipino, French, Hindi, Korean, Malay, Slovak, Slovenian,
and Thai.
Psychometric Information
Method of development. Prior to the development of
the BPI, there was no speciﬁc instrument designed to the
intensity and impact of cancer pain that was brief and that
could be administered repeatedly over time to monitor
the effects of treatment. Existing measures at the time (e.g.,
the McGill Pain Questionnaire) were developed for non-
cancer pain. Based upon patient interviews, it was dis-
covered that existing questionnaires were too ambiguous,
irrelevant, or too lengthy for the assessment of cancer pain.
The questionnaire was developed in accordance with the
best guidelines for test construction available at the time
(i.e., the 1970s; Standards for Educational and Psycholog-
ical Tests published by the American Psychological Asso-
ciation, American Educational Research Association, and
by the National Council on Measurement in Education).
Item development was informed by patient interviews
and by ﬁeld testing of items. Even though this question-
naire was developed 30 years ago, the approach conforms
to the more recently published Draft Guidance for Indus-
try, Patient-Reported Outcome Measures: Use in Medical
Product Development to Support Labeling Claims by the
FDA. The BPI has since been validated for use as a brief
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and meaningful pain assessment tool for noncancer pain
conditions as well (17,18).
Acceptability. Acceptability was assessed in a non-
cancer pain population. The BPI was readily accepted
by patients, was not associated with excessive missing
data, and did not have problematic ﬂoor/ceiling effects
(20).
Reliability. Internal consistency for the Pain Severity
Score and for the Interference scale has been reported as
being 0.85 and 0.88, respectively, in noncancer pain pop-
ulations (18). Test–retest reliability has been assessed for
both cancer and noncancer forms of pain and for over
varying time frames. For very short time intervals (e.g.,
30–60 minutes), the test–retest reliability was 0.98 for
pain severity and 0.97 for pain interference (21). Test–
retest reliability for daily administration ranges between
0.83–0.88 for pain severity and between 0.83–0.93 for
pain interference (22). FM is considered to be a form of
noncancer or musculoskeletal pain and as such these met-
rics could be applied to FM; however, formal assessment
of reliability of the BPI in FM is not available.
Validity. Item analysis has consistently revealed a
2-factor structure (severity or intensity and interference) in
more than 36 studies of the BPI across multiple languages
for both cancer and noncancer pain populations (23). Con-
struct validity of the BPI has been supported for the ge-
neric assessment of pain as well as speciﬁcally for low
back pain, rheumatoid arthritis (17), and osteoarthritis
(20). In a sample of patients with arthritis, the BPI pain
severity score correlated (r  0.74) with the bodily
pain scale of the Short Form 36, a generic measure of pain
intensity, and (r  0.77) with the Chronic Pain Grade
Intensity scale, another generic pain intensity measure.
The BPI Interference scale from this same sample corre-
lated (r  0.81) with the Chronic Pain Grade disability
scale, and (r  0.69) with the Health Assessment Ques-
tionnaire disability index, a disease-speciﬁc measure of
functional interference (17).
Ability to detect change. The BPI has demonstrated
response to change in response to many forms of
pharmacologic and nonpharmacologic treatments (23). In
chronic pain states, generally, an improvement of 30% or
2–3 points improvement is considered to be a clinically
meaningful change (24–26). In a pooled analysis across 12
weeks of treatment from 4 randomized controlled trials
of duloxetine for ﬁbromyalgia (FM), the BPI “average
pain” and the “Pain Severity Score” was anchored against
the Patient Global Impression of Improvement scale
(PGI-I). Anchor-based minimum clinically important dif-
ferences for the “average” pain and for the PGI-I were
calculated based upon the difference in mean change
from baseline to end point resulting in values of 2.1 and
2.2 points, respectively. This amount of change was asso-
ciated with 32% and 34% reductions in pain from the
baseline scores, respectively (27).
References. The user manual for the BPI contains a
reference listing of 72 studies supporting the valid use of
the BPI across a wide variety of chronic pain conditions,
including FM (23).
Critical Appraisal of Overall Value to the
Rheumatology Community
Strengths. The BPI was designed to monitor change in
pain (and its impact) over time. Numerous studies support
its validity to function in this capacity.
Caveats and cautions. The BPI is an industry standard
for the generic assessment of both cancer and noncancer
pain conditions and contains few ﬂaws in terms of psy-
chometrics, ease of administration, or utility. Far more is
known about the psychometrics of the Pain Severity scale
and the Pain Interference scale than about the other fea-
tures of the questionnaire (pain relief, body map, etc.).
These other features are often not reported in trials using
this instrument. Reports speciﬁcally focused upon the
psychometric evaluation of the BPI in FM are not avail-
able; however, FM is classiﬁed as a chronic noncancer
musculoskeletal pain condition and the validity of the BPI
is supported for the generic assessment of pain intensity
and interference.
Clinical usability. The BPI is recommended for use in
clinical settings to monitor the severity and impact of pain
generically.
Research usability. The BPI is recommended as tool of
choice for the assessment of pain in clinical pain trials
(28). It is easily administered and has low patient burden.
MULTIDIMENSIONAL FATIGUE INVENTORY
(MFI-20)
Description
Purpose. The MFI-20 was introduced 1995 (29) as a
measure of fatigue severity. Fatigue is perhaps the most
common complaint heard by clinicians. Apart from the
everyday use of the term to describe normal tiredness, it
can be used to indicate the presence of disease (29). There-
fore, the MFI-20 was developed to function as an index of
disease, as a diagnostic criterion, or as an outcome variable
when a treatment is being evaluated.
Content. The MFI-20 possesses 5-factor analytically
conﬁrmed subscales assessing general fatigue, physical
fatigue, reduced activity, reduced motivation, and mental
fatigue. The MFI differs from other multidimensional fa-
tigue measures by purposely retaining a relatively short
list of items, and by eliminating somatic items.
Number of items. The MFI-20 contains 20 items.
Response options/scale. The MFI-20 uses the same re-
sponse set for each of the 20 items. The respondent is
asked to mark an X in 1 of 5 boxes arranged linearly and
anchored by “yes, that is true” at one pole to “no, that is
not true” at the opposite pole. Scoring of scales requires
some items to be reversed such that a higher score on each
scale is indicative of greater fatigue.
Recall period for items. The time frame is somewhat
nonspeciﬁc as the questionnaire queries for symptoms oc-
curring “lately.”
Endorsements/examples of use. The MFI-20 has been
used in numerous clinical populations, including cancer
(30), Sjo¨gren’s syndrome (31), craniopharyngioma (32),
myelodysplastic patients (33), chronic fatigue syndrome
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(29), ﬁbromyalgia (FM) (34), and general chronic pain (35).
It has also been validated for use in nonclinical samples,
including psychology students, medical students, Army
recruits, and junior physicians (29).
Practical Application
How to obtain. The MFI-20 is available from the author:
E. M. A. Smets, Academic Medical Centre, University of
Amsterdam, Department of Medical Psychology, Amster-
dam, The Netherlands.
Method of administration. The MFI-20 is a self-report
questionnaire.
Scoring. Each scale can be calculated by summing the
speciﬁc items within each scale. Some items need to be
reverse scored prior to summing.
Score interpretation. Each scale contains 4 items with
a maximum value of 20 (i.e., each item is endorsed with a
“5”) and a minimum value of 4 (i.e., each item is endorsed
with a “1”). Higher scores on each scale indicate more
fatigue severity.
Respondent burden. It takes approximately 5 minutes
to complete the MFI-20.
Administrative burden. The MFI-20 is easily adminis-
tered by handing the questionnaire to the participant.
Scoring is accomplished by reverse scoring the required
items and then summing each of the 5 scales. Scoring can
be completed in 5 minutes.
Translations/adaptations. Validated translations are
available for the following languages: English, Swedish,
French, and German.
Psychometric Information
Method of development. At the time of development,
both 1-dimensional and multidimensional measures of
fatigue existed but were quite lengthy and confounded by
somatic items. With a consideration of the legacy measures
of the time, development of the MFI was initiated by
postulating the existence of 5 dimensions of fatigue.
Items were generated and then ﬁeld tested in a diverse
group of individuals expected to experience a wide range
of fatigue, including individuals with cancer, individuals
with chronic fatigue syndrome, ﬁrst-year medical and psy-
chology students, junior physicians, and Army recruits.
Conﬁrmatory factor analysis supported the retention of the
5-dimensional model inherent in this instrument (29).
Acceptability. The MFI is not associated with excessive
missing data problems or with or ﬂoor/ceiling effects (36).
Reliability. In the original validation study, internal
consistency (Cronbach’s alpha) for the 5 scales ranged
between 0.53–0.93 with the average being 0.80 (29). A
more recent validation study of the MFI-20 conducted in
the US with a general population sample found the fol-
lowing Cronbach’s alpha values: general fatigue (0.83),
physical fatigue (0.81), reduced activity (0.82), reduced
motivation (0.71), and mental fatigue (0.86) (36). Internal
consistency of a total of all 20 items was 0.93. Test–retest
reliability has not been reported.
Validity. Conﬁrmatory factor analysis has repeatedly
found a 5-factor solution as best ﬁtting the data (i.e., gen-
eral fatigue, physical fatigue, reduced motivation, reduced
activity, mental fatigue), each with adjusted goodness of ﬁt
indexes above 0.90 (30). Convergent validity was sup-
ported by comparing each scale to a visual analog scale
(VAS) assessing fatigue. Associations were all signiﬁcant
with the general fatigue scale having the strongest relation-
ship (30). Construct validity for each scale in association
with other relevant constructs has been supported in sev-
eral validation studies for the MFI-20 (29,30,36).
Ability to detect change. Formally established mini-
mum clinically important differences have not been pub-
lished for the MFI-20 in FM, however each of the scales
appear to be responsive to treatment changes, especially
the general fatigue scale (30).
References. There is no speciﬁc user manual but the
original manuscript provides details on the development
and psychometrics of the instrument (29).
Critical Appraisal of Overall Value to the
Rheumatology Community
Strengths. The MFI-20 is a brief measure of fatigue that
appears to capture relevant dimensions of fatigue severity.
It has been used successfully in FM and appears to be a
good marker of illness across a broad range of medical
illnesses. While not as brief as a single-item VAS (as is
commonly used), the MFI-20 correlates well with these
measures but offers greater clariﬁcation of the type of
fatigue being experienced and offers better assessment
precision than single-item measures. The MFI does a
good job of capturing the experience of fatigue across
multiple dimensions without being contaminated by con-
structs such as functional status (i.e., the functional impact
of fatigue), which is better assessed by functional status
measures.
Caveats and cautions. Five levels of “yes, that is true”
to “no, that is not true” represent a difﬁcult response set
for some patients to interpret.
Clinical usability. The MFI-20 may be too lengthy for
the typical clinic where a briefer screen may be more
appropriate. If however there is a desire to track speciﬁc
forms of fatigue over time, then this is an appropriate
measure.
Research usability. The MFI-20 is recommended for
use in clinical trials of interventions targeting fatigue. It
has been used successfully in clinical trials of FM (37).
MEDICAL OUTCOMES STUDY (MOS) SLEEP
SCALE
Description
Purpose. The MOS Sleep Scale was originally devel-
oped as part of the MOS, which was a 4-year observational
study of health outcomes for chronically ill patients. The
MOS Sleep Scale represents the portion of this larger as-
sessment protocol that speciﬁcally focused upon sleep
(38). The MOS Sleep Scale is a non–disease-speciﬁc mea-
sure of multiple aspects of sleep problems.
Content. The MOS Sleep Scale is a 12-item measure
assessing 6 domains of sleep: 1) sleep disturbance (e.g., the
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ability to fall and stay asleep), 2) sleep adequacy (e.g.,
sleeping enough to feel rested and restored), 3) sleep quan-
tity (e.g., the number of hours slept), 4) somnolence (e.g.,
daytime sleepiness), 5) snoring, and 6) shortness of breath
or headache.
Number of items. The MOS Sleep Scale contains 12
items in its original form; this form has been used in the
context of ﬁbromyalgia (FM) clinical trials (37,39) and will
be the focus of this review. A briefer 6-item version is also
available from the publisher.
Response options/scale. The MOS Sleep Scale uses a
variety of response sets. Item 1 queries about how long it
takes to fall asleep. Response options are blocked into
“0–15 minutes,” “16–30 minutes,” “31–45 minutes,”
“46–60 minutes,” and “more than 60 minutes.” Item 2
queries about how many hours of sleep were obtained on
average over the past 4 weeks. This is an open-ended
question ranging between 0–24 hours. The remaining 10
items use a 6-point response set based upon the following
values and anchors (1  all of the time, 2  most of the
time, 3  a good bit of the time, 4  some of the time, 5 
a little of the time, and 6  none of the time).
Recall period for items. The time frame for each item is
the past 4 weeks. An acute 1-week recall version is also
available.
Endorsements/examples of use. The MOS Sleep Scale
has been used in numerous nonclinical and clinical pop-
ulations, including a general US sample (40), cancer pain
(41), restless legs syndrome (42), overactive bladder (43),
rheumatoid arthritis (44), dialysis (45), neuropathic pain
(46), and FM (47).
Practical Application
How to obtain. The MOS Sleep Scale is available from
its publisher, Quality Metric. More information can be
found at URL: QualityMetric.com. It is recommended that
the interested user contact the publisher to learn about
potential pricing or licensing agreements associated with
the use of this instrument.
Method of administration. The MOS Sleep Scale is a
self-report questionnaire.
Scoring and score interpretation. Each scale can be
hand scored. Some scales are single items and do not
require scoring while others require items to be reversed
and summed. Each scale (except sleep quantity) is recali-
brated onto a 0–100 scale. For most scales, higher scores
indicate worse sleep problems. The exceptions are sleep
adequacy and sleep quantity where lower scores indicate
worse sleep problems. The MOS Sleep Scale can be aggre-
gated to produce 2 summary indices, the Sleep Problems
Index II (9 items) and the Sleep Problems Index I (6 items).
Each of these indices integrates the domains of sleep dis-
turbance, sleep adequacy, shortness of breath, and somno-
lence into a single score. The difference between Sleep
Problems Index 1 and 2 is simply length rather than do-
main coverage; potentially overlapping items were elimi-
nated in Index 1. Higher scores on either index are indic-
ative of worse sleep problems.
Respondent burden. It takes approximately 3–5 min-
utes to complete the MOS Sleep Scale.
Administrative burden. The MOS Sleep Scale is easily
administered by handing the questionnaire to the partici-
pant. Scoring requires some reverse scoring, recalibrating
scales onto a 0–100 scale, and aggregating the 2 summary
indices. It can take 5–7 minutes to score.
Translations/adaptations. The 12-item version is avail-
able in 85 languages, which are available from the pub-
lisher.
Psychometric Information
Method of development. The MOS Sleep Scale was de-
veloped using an extensive review of the published sleep
literature resulting in the selection of the domains con-
tained in the scaling of this instrument. The intent was to
construct an instrument that would identify sleep prob-
lems across sleep-related diseases and associated illnesses
rather than being speciﬁc to any one type of problem. The
scale was initially ﬁeld tested in a large sample of healthy
individuals as well as individuals with a variety of chronic
illnesses associated with the MOS (42).
Acceptability. In an evaluation of the MOS Sleep Scale
in neuropathic pain, missing items were observed in
10% of the sample. Ceiling and ﬂoor effects for each item
were acceptable (i.e., 0.50% of all cases). A single item,
“awakening short of breath,” accounted for much of the
problems in scaling properties (46). A second study found
similar characteristics for a restless legs syndrome sample
with 5% of cases experiencing ﬂoor or ceiling effects for
the scale as a whole and 20% experiencing ﬂoor or
ceiling effects for summed scales and50% for individual
items (42).
Reliability. Taken from the neuropathic pain study
above (46), Cronbach’s alpha ranged between 0.64–0.84
for the MOS sleep subscales. In restless legs syndrome
all scales exceeded Cronbach’s alpha of 0.70 with the
exception of somnolence (  0.66) (42). In a study of FM
all multi-item scales (i.e., sleep disturbance, sleep ade-
quacy, somnolence, and summary indices) exceeded  
0.70 (47).
Validity. Support for construct validity was identiﬁed
in the restless legs syndrome study where worsening MOS
sleep domain scores correlated strongly with worsening
indices of quality of life (42). Multitrait scaling was used in
the neuropathic pain sample to support convergent and
divergent construct validity (46) and recently, conﬁrma-
tory factor analysis has supported the factorial structure of
the MOS Sleep Scale in FM (47). Qualitative interviews
(i.e., cognitive debrieﬁng) with patients with FM demon-
strated that the MOS Sleep Scale was of relevance to
individuals with FM and adequately captured the experi-
ence of sleep difﬁculties arising in FM (48). Additional
work associated with criterion validity is needed for the
MOS Sleep Scale when speciﬁcally applied to FM.
Ability to detect change. In a neuropathic pain sample,
the minimal important difference for the 9-item Problem
Index 2 was 5.1 (scale 0–100) (46). This is considered a
moderate effect (0.65) and corresponds to the corrected
change in a group of patients demonstrating change con-
trasted to the variation observed in a group of patients
demonstrating no change. A study in FM reported a clin-
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ically important difference (CID) for the sleep disturbance
subscale as being 7.9 points (47). CID was calculated by
examining differences from baseline as a function (i.e.,
anchored) of the Patient Global Impression of Change.
References. The publisher, Quality Metric, provides ref-
erences regarding the development and psychometrics of
this instrument.
Critical Appraisal of Overall Value to the
Rheumatology Community
Strengths. The MOS Sleep Scale is widely used and is a
generic measure of sleep problems that can be used to
compare different clinical populations to one another on a
common metric. The questionnaire is brief, responsive to
change, and has been used in FM.
Caveats and cautions. The items do not use a uniform
structure and the scoring is relatively complex given its
brevity. The interpretation of the 2 composite indices is
not completely obvious except that they are a combina-
tion of the assessed domains. Additional data supporting
validity and responsiveness to change in FM are desirable.
Clinical usability. The MOS Sleep Scale can be used
clinically to monitor changes in sleep across time and
within broadly based domains of sleep problems; how-
ever, it is a bit lengthy for routine clinical use (48).
Research usability. The MOS Sleep Scale can be used
to monitor treatment effects and appears to be sensitive to
change both in sleep and in overall quality of life when
sleep or other related symptoms improve or worsen.
MULTIPLE ABILITY SELF-REPORT
QUESTIONNAIRE (MASQ)
Description
Purpose. The MASQ was purposely designed to assess
the self-perception of cognitive difﬁculties in contrast to
the more traditional “objective” neuropsychological as-
sessment by a clinician (49). At the time of development,
there were several measures of perceived memory prob-
lems, but other relevant areas of cognition lacked a valid
self-appraisal tool.
Content. The MASQ contains items about perceived
cognitive difﬁculties in 5 domains of clinical neuropsy-
chological evaluation. The domains of the MASQ along
with neuropsychological tests commonly used to index
each domain are (50) language (L): Boston Naming Test,
Controlled Oral Word Association (C, F, and L words
and animals); visual-perceptual ability (VP): Wechsler
Adult Intelligence Test Revised (WAIS-R; Block Design,
Judgment of Line Orientation); verbal memory (VM): Cal-
ifornia Verbal Learning Test (Trials 1–5 total, Long Delay
Free Recall), Wechsler Memory Scale Revised (WMS-R;
Logical Memory I and II); visual-spatial memory (VSM):
Rey-Osterrieth Complex Figure (immediate and delayed
reproduction), WMS-R Visual Reproduction I and II; and
attention/concentration (AC): Stroop Color-Word Test,
WAIS-R Arithmetic, WAIS-R Digit Span.
Number of items. The MASQ contains 38 items.
Response options/scale. The MASQ uses the same
5-point response set for all items verbally anchored by
“never,” “rarely,” “sometimes,” “usually,” and “always.”
The 5 scales (i.e., L, VP, VM, VSM, AC) are summed. A
total score is produced by combining all items.
Recall period for items. No time frame is indicated on
the original form.
Endorsements/examples of use. The MASQ has been
used to assess perceived cognitive problems in several
populations, including the following: epilepsy (49–51),
adjuvant chemotherapy for breast cancer (52), breast can-
cer survivors (53), and ﬁbromyalgia (FM).
Practical Application
How to obtain. The MASQ is available through the in-
strument’s author: Michael Seidenberg, Department of
Psychology, UHS/CMS, 3333 Green Bay Road, North Chi-
cago, IL 60064.
Method of administration. The MASQ is administered
as a self-report questionnaire.
Scoring. Each item is scaled between 1–5. Nearly half of
the items require reverse scoring prior summing. Each
scale is then summed. A total score containing all items is
also possible. The maximum score for the total score is 190
(i.e., 38 items  5). Scales containing 8 items (i.e., L, VM,
VSM, AC) have a maximum score of 40 and VP (6 items)
has a maximum score of 30.
Score interpretation. Higher scores on any scale in-
dicate greater perceived difﬁculties with that cognitive
domain.
Respondent burden. It takes approximately 10 minutes
to complete the MASQ.
Administrative burden. The MASQ is easily adminis-
tered by handing the questionnaire to the participant.
Scoring is relatively simple but does require reverse scor-
ing for nearly half of the items before summing.
Translations/adaptations. The MASQ is available in
English.
Psychometric Information
Method of development. The initial version of the
MASQ contained 48 items based upon clinical experience
and a review of published questionnaires at the time of
development. Content relevance was evaluated by 8 clin-
ical neuropsychologists and 1 neuropsychiatrist with re-
spect to the cognitive function depicted by each item.
Agreement among raters for the retained items supports
the content validity of each item.
Acceptability. In the development sample, 22% missed
at least 1 item. Ceiling and ﬂoor effects were not reported.
Reliability. In the original validation sample, Cron-
bach’s alpha was 0.92 for the total score. Internal consis-
tency was above 0.70 for each of the individual scales (49).
In other clinical samples, similar reliability estimates have
been reported (e.g.,   0.93 for total and ranged from
0.72–0.79 for subscales in breast cancer survivors) (53).
In the original validation study, 2-month test–retest re-
liability for the entire questionnaire was 0.71 and ranged
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between 0.55 (L) and 0.74 (VM) (49). Test–retest data and
internal consistency data is not available for FM.
Validity. In the original development of the MASQ,
items were ﬁeld tested in 2 samples, individuals with
unilateral temporal-lobe epilepsy and healthy normal
individuals. Support for concurrent validity came from
higher MASQ scores being associated with poorer perfor-
mance on neuropsychological tests in both samples but
with greater perceived difﬁculties being observed in the
clinical sample. These studies support the idea that per-
ceived cognitive difﬁculties correspond to more objec-
tively assessed indices of the same constructs (49). In a
study comparing individuals with FM to healthy controls,
individuals with FM scored signiﬁcantly higher on each
MASQ subscale than did healthy controls (54). Studies
assessing the criterion validity of the MASQ with objective
neuropsychological performance tests in FM are not cur-
rently available.
Ability to detect change. Reliable change indices and
standard regression-based change norms have been estab-
lished for the MASQ for use in cases of epilepsy (51). The
MASQ has also demonstrated response to change in clin-
ical trials of therapeutics for FM (e.g., milnaciparan) (55).
References. Original support for the MASQ is found in
the work by Seidenberg et al (49).
Critical Appraisal of Overall Value to the
Rheumatology Community
Strengths. Fibro fog is a common complaint among in-
dividuals with FM. Often only the memory aspects are
assessed, but patients complain of broader deﬁcits that are
covered by the MASQ. The MASQ can be useful in track-
ing the varied manifestations of dyscognition in FM that
are related to the different symptoms that characterize FM.
Caveats and cautions. The length of this instrument at
38 items may be prohibitive in settings where multiple
domains of clinical relevance need to be efﬁciently mea-
sured. The MASQ has not been as rigorously developed or
tested as the other measures reviewed in this article, but is
one of the few measures currently available to assess this
important aspect of FM.
Clinical usability. The MASQ appears to capture mul-
tiple aspects of ﬁbro fog. Patients express a desire to have
this domain assessed; yet, there are few instruments aside
from the MASQ that are available for this purpose.
Research usability. The MASQ has been used in several
large scale clinical trials of therapeutics for FM supporting
is ability to assess and detect change in perceived cogni-
tive difﬁculties.
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